Articles

Find an Article

Filter articles

Applied Filters

Showing 91 to 100 of 122 results

Adapt or die: how to survive the patent cliff

India, US16-10-2013

Many of the world’s biggest selling drugs have lost exclusivity in recent years, presenting huge opportunities for generic drugs companies but, as LSIPR finds out, it doesn’t have to be a dead end for the innovators.

'Because he fears': should generics fear the high court's quia timet injunctions?

UK16-10-2013Bethan Hopewell and Geraldine Quinn

For generic drug makers, previous bad behaviour may affect new litigation, especially when it comes to injunctions, as Bethan Hopewell and Geraldine Quinn explain.

Personalised medicine: patenting new drugs from old

28-06-2013Paul England

The law of patents and SPCs has yet to be tested in the context of medicines which can be used to treat specific groups of patients, as Paul England explains.

A global approach: Novo Nordisk's IP strategy

EU30-04-2013

While the global trend is towards a “more hostile IP environment” for pharmaceutical companies, Danish healthcare giant Novo Nordisk A/S continues to perform. LSIPR talks to Lars Kellberg, corporate vice president, about how it meets the challenges.

India: a threat to an industry or just misunderstood?

India01-04-2013

To read much of the reaction to recent pharmaceutical rulings in India, you might think that the country is waging a war against Western innovation. But while there is certainly cause for concern, that’s not the whole story, as LSIPR finds out.

Post-grant patent challenges in Europe and the US: harmony at last?

EU, US01-04-2013Jane Wainwright and Daniel Young

Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives.

Generic battles: pay-for-delay in Brazil

Brazil01-04-2013Gabriel Di Blasi

While no court has tested it, Brazilian legislation seems to prohibit pay-for-delay settlements in the pharmaceutical industry. Gabriel Di Blasi argues that it’s time for a test case.

Moving forward: biologics and biocomparables in Mexico

Mexico01-04-2013Daniel Sánchez and Victor Ramirez

Biocomparable medicines are currently among the hottest topics in regard to life sciences legislation in Mexico. Daniel Sánchez and Victor Ramirez investigate.

The European take on the Bolar provision: conclusions from Astellas v Polpharma

Poland01-04-2013Rafał Witek

While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains.

The likely role of the UPC in pharma patent litigation

EU28-03-2013

The recent agreement on a Unified Patent Court in Europe raises questions for patent holders in all industries. Trevor Cook looks at the potential impact on pharmaceutical patent litigation.

Showing 91 to 100 of 122 results

LSIPR